

## CHANGE OF COMPANY NAME TO NEXALIS THERAPEUTICS

The Board of InhaleRx Limited (**IRX** or the **Company**) advises that the Australian Securities and Investments Commission (**ASIC**) has issued a Certificate of Change of Name to the Company, confirming the new name of Nexalis Therapeutics Ltd.

The name change was approved by a requisite majority of shareholders as a special resolution at the General Meeting held on 29 January 2026.

The Company has since received confirmation from the Australian Securities Exchange (**ASX**) that the Company's securities will be listed as Nexalis Therapeutics Ltd under the ASX ticker code of NX1, effective Tuesday, 17 February 2026.

Shareholders are not required to take any action as the change of name and ASX ticker will be processed automatically.

Authorised for release by the Board of Directors.

### **For further information:**

[www.nexalisterapeutics.com](http://www.nexalisterapeutics.com)

James Barrie, Company Secretary

T: +61 3 9070 1221

E: [investors@nexalisterapeutics.com](mailto:investors@nexalisterapeutics.com)

### **Investor relations**

Matthew Wright

NWR Communications

M: 0451 896 420

E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

## **ABOUT NEXALIS THERAPEUTICS LTD (ASX: NX1)**

Nexalis Therapeutics Ltd is an Australian Clinical Stage Drug Development Company that is developing rapid onset, inhaled therapies to address unmet medical needs in pain management and mental health sectors. The Company has secured a funding partner with a facility of up to \$52.3m to accelerate the development of IRX-211 to treat Breakthrough Cancer Pain (“BTcP”), IRX-616a to treat Panic Disorder (“PD”) and SRX-25 for the treatment of Treatment-Resistant Depression (“TRD”).

The overarching goal is to pursue U.S. FDA approval and registration using rapid and cost-effective regulatory pathways, such as 505(b)(2).

There is a significant economic opportunity for NX1 and the Company's shareholders, the clinical indications under investigation have been carefully selected in consultation with regulatory authorities. Bringing new approved medications to market will address critical gaps whereby there's currently mismatched treatment options that can carry dependency concerns.